ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.
Frequently asked questions
What sector does ZYUS Life Sciences Corporation (ZYUS) operate in?
ZYUS Life Sciences Corporation belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is ZYUS Life Sciences Corporation (ZYUS) current stock price?
As of the latest data, ZYUS Life Sciences Corporation stock price is CA$0.50, with a previous close of CA$0.50.
What is ZYUS Life Sciences Corporation (ZYUS) current market capitalization?
ZYUS Life Sciences Corporation market cap is approximately 40.26 million.
What is ZYUS Life Sciences Corporation (ZYUS) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.27.
Does ZYUS Life Sciences Corporation (ZYUS) pay dividends?
No. ZYUS Life Sciences Corporation does not pay a dividend.
When is ZYUS Life Sciences Corporation (ZYUS) next earnings report?
ZYUS Life Sciences Corporation is expected to release its next earnings report on June 30, 2026.
What is ZYUS Life Sciences Corporation (ZYUS) beta (volatility) score?
ZYUS Life Sciences Corporation has a beta of 0.452, indicating lower volatility than the overall market.
